The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy
TC Knepper, M Montesion, JS Russell, ES Sokol… - Clinical Cancer …, 2019 - AACR
Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
[HTML][HTML] The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
TC Knepper, M Montesion, JS Russell… - … cancer research: an …, 2019 - ncbi.nlm.nih.gov
Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy which
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
TC Knepper, M Montesion, JS Russell… - … Cancer Research: an …, 2019 - europepmc.org
Purpose Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
[PDF][PDF] The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
TC Knepper, M Montesion, JS Russell, ES Sokol… - researchgate.net
Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy which
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
TC Knepper, M Montesion… - … : an official journal …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
TC Knepper, M Montesion, JS Russell… - Clinical Cancer …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Purpose:</jats: title>< jats: p>
Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which has …
Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which has …
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
TC Knepper, M Montesion, JS Russell… - … Cancer Research: an …, 2019 - europepmc.org
Purpose Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …
has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the …